指南与共识哮喘

嗜酸性与非嗜酸性哮喘:全球真实世界重症哮喘队列中表型特征专家共识框架

Eosinophilic and Noneosinophilic Asthma: An Expert Consensus Framework to Characterize Phenotypes in a Global Real-Life Severe Asthma Cohort.
指南 / 共识 · Chest · 2021-04-19

结果显示嗜酸性表型占绝大多数(83.8%为最可能,8.3%为可能),非嗜酸性仅1.6%。嗜酸性表型患者起病更晚、肺功能更差,非嗜酸性表型更多为女性且合并湿疹、使用抗IgE和LTRA。

要点

  • 重症哮喘中嗜酸性表型占83.8%(最可能)和8.3%(可能),非嗜酸性仅1.6%。
  • 嗜酸性表型起病更晚(29.1岁 vs 6.7岁),肺功能更差(FEV1%pred 76.1% vs 89.3%)。
  • 非嗜酸性表型更多为女性(81.5% vs 62.9%),合并湿疹更常见(20.8% vs 8.5%)。

核心结论

  • 在真实世界重症哮喘队列中,嗜酸性表型比既往认知更常见,且表型特征 distinct。
  • 该梯度算法使用初级和专科诊疗中易获取的变量,有助于识别可治疗特质并提高治疗精准性。

研究设计与样本

  • 历史性登记研究,纳入国际重症哮喘登记处(ISAR)11个国家2015年1月1日至2019年9月30日入组的成人重症哮喘患者。

主要发现

  • 83.8%患者为最可能嗜酸性表型(3级),8.3%为可能(2级),6.3%为最不可能(1级),1.6%为非嗜酸性表型(0级)。
  • 嗜酸性表型(2级或3级)患者起病年龄更晚(29.1岁 vs 6.7岁;P < .001),肺功能更差(支气管舒张后FEV1占预计值百分比76.1% vs 89.3%;P = .027)。
  • 非嗜酸性表型患者更可能为女性(81.5% vs 62.9%;P = .047),合并湿疹(20.8% vs 8.5%;P = .003),使用抗IgE治疗(32.1% vs 13.4%;P = .004)和白三烯受体拮抗剂(50.0% vs 28.0%;P = .011)。

临床怎么用

  • 临床可采用基于最高血嗜酸粒细胞计数、长期OCS使用、FeNO升高、鼻息肉和成人起病哮喘的多组分梯度算法识别重症哮喘嗜酸性表型。
  • 识别嗜酸性与非嗜酸性表型有助于制定精准治疗策略,如抗IgE或白三烯受体拮抗剂的应用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Phenotypic characteristics of patients with eosinophilic and noneosinophilic asthma are not well characterized in global, real-life severe asthma cohorts. RESEARCH QUESTION: What is the prevalence of eosinophilic and noneosinophilic phenotypes in the population with severe asthma, and can these phenotypes be differentiated by clinical and biomarker variables? STUDY DESIGN AND METHODS: This was an historical registry study. Adult patients with severe asthma and available blood eosinophil count (BEC) from 11 countries enrolled in the International Severe Asthma Registry (January 1, 2015-September 30, 2019) were categorized according to likelihood of eosinophilic phenotype using a predefined gradient eosinophilic algorithm based on highest BEC, long-term oral corticosteroid use, elevated fractional exhaled nitric oxide, nasal polyps, and adult-onset asthma. Demographic and clinical characteristics were defined at baseline (ie, 1 year before or closest to date of BEC). RESULTS: One thousand seven hundred sixteen patients with prospective data were included; 83.8% were identified as most likely (grade 3), 8.3% were identified as likely (grade 2), and 6.3% identified as least likely (grade 1) to have an eosinophilic phenotype, and 1.6% of patients showed a noneosinophilic phenotype (grade 0). Eosinophilic phenotype patients (ie, grades 2 or 3) showed later asthma onset (29.1 years vs 6.7 years; P < .001) and worse lung function (postbronchodilator % predicted FEV1, 76.1% vs 89.3%; P = .027) than those with a noneosinophilic phenotype. Patients with noneosinophilic phenotypes were more likely to be women (81.5% vs 62.9%; P = .047), to have eczema (20.8% vs 8.5%; P = .003), and to use anti-IgE (32.1% vs 13.4%; P = .004) and leukotriene receptor antagonists (50.0% vs 28.0%; P = .011) add-on therapy. INTERPRETATION: According to this multicomponent, consensus-driven, and evidence-based eosinophil gradient algorithm (using variables readily accessible in real life), the severe asthma eosinophilic phenotype was more prevalent than previously identified and was phenotypically distinct. This pragmatic gradient algorithm uses variables readily accessible in primary and specialist care, addressing inherent issues of phenotype heterogeneity and phenotype instability. Identification of treatable traits across phenotypes should improve therapeutic precision.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Heaney LG, Perez de Llano L, Al-Ahmad M, et al. Eosinophilic and Noneosinophilic Asthma: An Expert Consensus Framework to Characterize Phenotypes in a Global Real-Life Severe Asthma Cohort. Chest. 2021. PMID: 33887242. doi:10.1016/j.chest.2021.04.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。